Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 12/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28283099 | 0.88 | CYP1A2 (0.63) | ADRB2CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL3674989 | 0.84 | TUBB4A (0.68) | ADRB2CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL10585167 | 0.84 | ADRB2 (0.47) | ADRB2CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL11579350 | 0.83 | LDHA (0.58) | CYP1A2CYP2D6CYP2C19LDHASLC6A4 | |
| SCHEMBL389941 | 0.82 | TUBB4A (0.57) | ADRB2LDHASLC6A4 | |
| SCHEMBL28849551 | 0.81 | CALM1 (0.58) | ADRB2CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL28615668 | 0.81 | PPARG (0.55) | ADRB2CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL2334749 | 0.79 | SLC6A4 (0.67) | CYP1A2CYP2D6CYP2C19LDHASLC6A4 | |
| SCHEMBL5859651 | 0.79 | LDHA (0.62) | CYP1A2CYP2D6CYP2C19LDHASLC6A4 | |
| SCHEMBL7767976 | 0.79 | ALDH1A1 (0.59) | CYP1A2CYP2D6CYP2C19LDHASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884508-A1 | Process for the preparation of polyhydroxylated stilbenes via claisen condensation | Portela & Ca., S.A. (PT) | 2008-02-06 | — | — | EP | claimed |
| EP-2049459-B1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8101804-B2 | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2202215-A2 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | Clariant Specialty Fine Chemicals (France) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049459-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | Clariant Specialty Fine Chemicals (France) (FR) | 2009-04-22 | — | — | EP | disclosed |
| EP-1884508-A1 | Process for the preparation of polyhydroxylated stilbenes via claisen condensation | Portela & Ca., S.A. (PT) | 2008-02-06 | — | — | EP | disclosed |
| WO-2008012108-A2 | PROCESS FOR THE PREPARATION OF POLYHYDROXYLATED STILBENES VIA CLAISEN CONDENSATION | PORTELA & CA., S.A. (PT) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012321-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | SQLE, SUCLA2, SORD | ADRB2 4158/4885CYP1A2 582/4885CYP2D6 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.